Olema Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

• Olema Pharmaceuticals Inc OLMA.OQ reported a quarterly adjusted loss of 51 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -49 cents. The mean expectation of eight analysts for the quarter was for a loss of 64 cents per share. Wall Street expected results to range from -70 cents to -53 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Olema Pharmaceuticals Inc's reported EPS for the quarter was a loss of 51 cents​.

• The company reported a quarterly loss of $33.57 million.

• Olema Pharmaceuticals Inc shares had fallen by 29.0% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Olema Pharmaceuticals Inc is $29.50

This summary was machine generated from LSEG data March 19 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)